The pharmaceutical giant saw its stock surge over 800% as its GLP-1 drugs Mounjaro and Zepbound created an entirely new blockbuster weight-loss medication category, outperforming #10 Eli Lilly's earlier pipeline expectations and capturing over 90% of the GLP-1 market share in 2024. This return is double that of Amazon's 500%, and combined Mounjaro and Zepbound sales exceeded $12 billion in 2023, over 30% more than the entire diabetes drug category average.
Comments on "Eli Lilly (LLY)"
Create a free account or sign in to join the discussion.
Sign in to join the conversation